BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32878569)

  • 1. PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease.
    Riccò B; Salati M; Reggiani Bonetti L; Dominici M; Luppi G
    Tumori; 2020 Dec; 106(6):NP57-NP62. PubMed ID: 32878569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report.
    Stueger A; Winder T; Tinguely M; Petrausch U; Helbling D
    J Immunother; 2019 Sep; 42(7):274-277. PubMed ID: 31219972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
    Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
    J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
    Sobecki-Rausch J; Barroilhet L
    Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed adenoneuroendocrine carcinoma of the non-ampullary duodenum with mismatch repair deficiency: a rare case report.
    Nozawa Y; Ishida K; Maiko N; Takada-Owada A; Onozaki M; Takaoka M; Matsuyama K; Sakuraoka Y; Nakazato Y; Kubota K
    Med Mol Morphol; 2022 Sep; 55(3):258-266. PubMed ID: 35596001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach.
    Ma F; Wang B; Xue L; Kang W; Li Y; Li W; Liu H; Ma S; Tian Y
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2135-2142. PubMed ID: 32306127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal mixed adenoneuroendocrine carcinoma (MANEC): An immunohistochemistry study of 13 microsatellite stable cases.
    Gurzu S; Fetyko A; Bara T; Banias L; Butiurca VO; Bara T; Tudorache V; Jung I
    Pathol Res Pract; 2019 Dec; 215(12):152697. PubMed ID: 31704155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed acinar-neuroendocrine carcinoma of the pancreas with positive for microsatellite instability: a case report and review of the literature.
    Yoshino K; Kasai Y; Kurosawa M; Itami A; Takaori K
    Surg Case Rep; 2023 Jun; 9(1):122. PubMed ID: 37386324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
    Ghatalia P; Nagarathinam R; Cooper H; Geynisman DM; El-Deiry WS
    Cancer Biol Ther; 2017 Sep; 18(9):651-654. PubMed ID: 28726535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
    Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
    J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: report of two cases.
    Gurzu S; Kadar Z; Bara T; Bara T; Tamasi A; Azamfirei L; Jung I
    World J Gastroenterol; 2015 Jan; 21(4):1329-33. PubMed ID: 25632209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
    Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
    J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy].
    Nakai M; Kawasaki H; Wajima N; Kimura A; Nakayama Y; Muroya T; Yonaiyama S; Okano K; Nagase H; Hakamada K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2301-3. PubMed ID: 24394092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.